Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 225 participants.

Also called NCT01286558

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 225 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01286558
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01286558. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2012-10-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
Condition
Hypertension
Intervention (Drug)
40 mg telmisartan
Intervention (Drug)
5 mg amlodipine
Intervention (Drug)
5 mg amlodipine
Intervention (Drug)
80 mg telmisartan
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct01286558
Content hash
1ff4ffc9d3e0ae8ee663b89fa0c4f4a5d33fb8ed413f99ef2ac5acda5523d247